Angle, a specialist medtech company based in England, is collaborating with the MD Anderson Cancer Center to investigate the clinical use of Angle's Parsortix system as a companion diagnostic in colorectal cancer. The University of Texas MD Anderson Cancer Center is a center devoted exclusively to cancer patient care, research, education and prevention.
The research collaboration is being led by Drs. Mien-Chie Hung, vice president for basic research and chairman of the department of molecular and cellular oncology; Scott Kopetz, associate professor, GI medical oncology; and Shulin Li, professor, pediatrics, the University of Texas MD Anderson Cancer Center.
MD Anderson will recruit 50 metastatic colorectal cancer patients for the patient study, which is expected to report by the end of the year. Blood will be collected from each patient and processed using Angle's Parsortix system. The harvested circulating tumor cells (CTCs) will be distributed to three different MD Anderson labs in pursuit of three key objectives: